U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C31H38N2O.2ClH
Molecular Weight 527.568
Optical Activity ( - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EZLOPITANT DIHYDROCHLORIDE

SMILES

Cl.Cl.COC1=CC=C(C=C1CN[C@H]2C3CCN(CC3)[C@H]2C(C4=CC=CC=C4)C5=CC=CC=C5)C(C)C

InChI

InChIKey=TYLAMTZGTVVECF-YBZGWEFGSA-N
InChI=1S/C31H38N2O.2ClH/c1-22(2)26-14-15-28(34-3)27(20-26)21-32-30-25-16-18-33(19-17-25)31(30)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24;;/h4-15,20,22,25,29-32H,16-19,21H2,1-3H3;2*1H/t30-,31-;;/m0../s1

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C31H38N2O
Molecular Weight 454.6462
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Ezlopitant (CJ-11974) is a non-peptide neurokinin-1 receptor antagonist. Pfizer was developing ezlopitant for the potential treatment of irritable bowel syndrome and chemotherapy-induced emesis. Development of ezlopitant has been discontinued.

CNS Activity

CNS Active
3913
Curator's Comment: Ezlopitant is CNS active in animals. No human data available.

Originator

Approval Year

Unknown
139594
PubMed

PubMed

TitleDatePubMed
Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis.
1999 Jan
Eziopitant. Pfizer.
2001 Oct
Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret.
2002 Nov
Patents

Patents

20010036943
6

Sample Use Guides

In Vivo Use Guide
Randomized phase II study of ezlopitant (CJ-11974) in the control of cisplatin-induced emesis. Patients were randomly assigned to two groups: group 1 received CJ-11,974 100 mg, and group 2 received placebo orally 30 minutes before and 12 hours after cisplatin and then twice daily on days 2 through 5 after cisplatin.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 18:40:33 UTC 2023
Edited
by admin
on Sat Dec 16 18:40:33 UTC 2023
Record UNII
XT268Z422D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EZLOPITANT DIHYDROCHLORIDE
Common Name English
1-Azabicyclo[2.2.2]octan-3-amine, 2-(diphenylmethyl)-N-[[2-methoxy-5-(1-methylethyl)phenyl]methyl]-, hydrochloride (1:2), (2S,3S)-
Systematic Name English
1-Azabicyclo[2.2.2]octan-3-amine, 2-(diphenylmethyl)-N-[[2-methoxy-5-(1-methylethyl)phenyl]methyl]-, dihydrochloride, (2S,3S)-
Systematic Name English
Code System Code Type Description
FDA UNII
XT268Z422D
Created by admin on Sat Dec 16 18:40:33 UTC 2023 , Edited by admin on Sat Dec 16 18:40:33 UTC 2023
PRIMARY
PUBCHEM
9958552
Created by admin on Sat Dec 16 18:40:33 UTC 2023 , Edited by admin on Sat Dec 16 18:40:33 UTC 2023
PRIMARY
CAS
331676-67-6
Created by admin on Sat Dec 16 18:40:33 UTC 2023 , Edited by admin on Sat Dec 16 18:40:33 UTC 2023
NON-SPECIFIC STOICHIOMETRY
CAS
223389-63-7
Created by admin on Sat Dec 16 18:40:33 UTC 2023 , Edited by admin on Sat Dec 16 18:40:33 UTC 2023
PRIMARY
Related Record Type Details
Structure of EZLOPITANT
PARENT -> SALT/SOLVATE
Structure of EZLOPITANT DIHYDROCHLORIDE DIHYDRATE
SOLVATE->ANHYDROUS
Related Record Type Details
Structure of EZLOPITANT
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966